IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1001-1025 out of 1284.

<< < 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>

Public Release: 7-Mar-2014
Journal of National Cancer Institute
Bone turnover markers predict prostate cancer outcomes
Biomarkers for bone formation and resorption predict outcomes for men with castration-resistant prostate cancer, a team of researchers from UC Davis and their collaborators have found.
National Institutes of Health

Contact: Dorsey Griffith
University of California - Davis Health System

Public Release: 7-Mar-2014
11th International Conference on Urban Health
New approach to prostate cancer screening needed
Manchester researchers surveyed more than 1,000 men and over 100 GPs about whether they would be happy with a risk-based approach to prostate cancer screening. The findings show over 80 percent of men expressed strong support and 77 percent of GPs were supportive.

Contact: Alison Barbuti
University of Manchester

Public Release: 7-Mar-2014
Journal of the National Cancer Institute
Cells appearing normal may actually be harbingers of lung cancer
Airways near lung tumors provide clues to the genetics of cancer.

Contact: Scott Merville
University of Texas M. D. Anderson Cancer Center

Public Release: 6-Mar-2014
Miami Breast Cancer Conference 2014
Molecular subtyping of breast cancer can better identify women at high risk of recurrence
A method called molecular subtyping can help doctors better determine which of their breast cancer patients are at high risk of getting breast cancer again, a new study led by the University of South Florida reports. This sophisticated genetic profiling of an individual's specific tumor offers an additional resource to help identify patients who would most benefit from chemotherapy and those who would not.

Contact: Anne DeLotto Baier
University of South Florida (USF Health)

Public Release: 6-Mar-2014
Cancer Cell
Common mutation is culprit in acute leukemia relapse
Harvard stem cell scientists have identified a mutation in human cases of acute lymphoblastic leukemia that likely drives relapse. The research, published in Cancer Cell, could translate into improved patient care strategies for this particular blood cancer, which typically affects children but is more deadly in adults.

Contact: Joseph Caputo
Harvard University

Public Release: 6-Mar-2014
Nature Communications
Enzyme controls transport of genomic building blocks
Our DNA and its architecture are duplicated every time our cells divide. Histone proteins are key building blocks of this architecture and contain gene regulatory information. Danish researchers show how an enzyme controls reliable and high-speed delivery of histones to DNA copying hubs in our cells. This shuttling mechanism is crucial to maintain normal function of our genes and prevent diseases as cancer. The results are published in the journal Nature Communications.
Danish Cancer Society, Danish National Research Foundation, Lundbeck Foundation

Contact: Katrine Sonne-Hansen
University of Copenhagen

Public Release: 6-Mar-2014
Meat Science
Eating red and processed meat -- what do scientists say?
Recent reports warn about a link between eating red and processed meat and the risk of developing cancer in the gut. These reports have resulted in new nutritional recommendations that advise people to limit their intake of red and processed meats. A recent perspective paper, authored by 23 scientists, published in the latest issue of journal Meat Science underlines the uncertainties in the scientific evidence.

Contact: Simon Jones

Public Release: 6-Mar-2014
Biology of Blood and Marrow Transplantation
Early detection helps manage a chronic graft-vs.-host disease complication
A simple questionnaire that rates breathing difficulties on a scale of zero to three predicts survival in chronic graft-vs.-host disease, according to a study published in the March issue of Biology of Blood and Marrow Transplantation.
National Institutes of Health

Contact: Kristen Woodward
Fred Hutchinson Cancer Research Center

Public Release: 6-Mar-2014
Anticancer Research
Vitamin D increases breast cancer patient survival
Breast cancer patients with high levels of vitamin D in their blood are twice as likely to survive the disease as women with low levels of this nutrient, report University of California, San Diego School of Medicine researchers in the March issue of Anticancer Research.
Congressional allocation to Milton S. Hershey Medical Center Penn State Cancer Institute

Contact: Yadira Galindo
University of California - San Diego

Public Release: 6-Mar-2014
Journal of Steroid Biochemistry and Molecular Biology
UT Arlington study links BPA and breast cancer tumor growth
A recent paper from researchers in Texas attempts to trace how bisphenol-A may promote breast cancer tumor growth with help from a molecule called RNA HOTAIR.
National Institutes of Health, American Heart Association

Contact: Traci Peterson
University of Texas at Arlington

Public Release: 6-Mar-2014
Cell Reports
Study identifies gene important to breast development and breast cancer
A new study in Cell Reports identifies a gene important to breast development and breast cancer, providing a potential new target for drug therapies to treat aggressive types of breast cancer.
The Breast Cancer Research Foundation, NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH/National Cancer Institute

Contact: Siobhan Gallagher
Tufts University, Health Sciences Campus

Public Release: 5-Mar-2014
Science of the Total Environment
Half of pregnant women are passive smokers, due above all to their partners
The University of the Basque Country is participating in the INMA project that studies childhood and the environment, and one piece of research has revealed the extent to which non-smoking pregnant women are under the effects of tobacco smoke.

Contact: Oihane Lakar Iraizoz
Elhuyar Fundazioa

Public Release: 5-Mar-2014
Science Translational Medicine
Going viral to target tumors
A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic virotherapy, an investigational intervention that employs viruses to destroy tumors.
Ludwig Cancer Research, Howard Hughes Medical Institute, and others

Contact: Rachel Steinhardt
Ludwig Institute for Cancer Research

Public Release: 5-Mar-2014
British Journal of Health Psychology
Patients have a right to know -- not a duty to know -- their diagnosis says new research
Defensive mechanisms protect patients from fully engaging with bad news say healthcare professionals from the University of Leicester.

Contact: Dr. Lynn Furber
University of Leicester

Public Release: 5-Mar-2014
New England Journal of Medicine
Younger men benefit most from surgery for localized prostate cancer
New study finds a substantial long-term reduction in mortality for men with localized cancer who undergo a radical prostatectomy.
Swedish Cancer Society, National Institutes of Health, Karolinska Institutet, Prostate Cancer Foundation, Percy Falk Foundation

Contact: Todd Datz
Harvard School of Public Health

Public Release: 5-Mar-2014
Journal of Hematology and Oncology
Novel cancer vaccine holds promise against ovarian cancer, mesothelioma
A novel approach to cancer immunotherapy may provide a new and cost-effective weapon against some of the most deadly tumors, including ovarian cancer and mesothelioma. Massachusetts General Hospital investigators report that a protein engineered to combine a molecule targeting a tumor-cell-surface antigen with another protein that stimulates several immune functions prolonged survival in animal models of both tumors.
Edmund Lynch Jr. Cancer Fund, Vaccine and Immunotherapy Center Mesothelioma Research and Resource Program, Friends of Vaccine and Immunotherapy Center Fund

Contact: Katie Marquedant
Massachusetts General Hospital

Public Release: 5-Mar-2014
Journal of Interferon & Cytokine Research
Can low-dose interferon prevent relapse of hepatitis C virus infection?
Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals. Low-dose oral interferon may reduce the risk of HCV relapse in patients with mild liver fibrosis according to a study published in Journal of Interferon & Cytokine Research.

Contact: Vicki Cohn
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 5-Mar-2014
Proceedings of the National Academy of Sciences
Researchers identify target for shutting down growth of prostate cancer cells
Scientists at UT Southwestern Medical Center have identified an important step toward potentially shutting down the growth of prostate cancer cells.

Contact: Patrick McGee
UT Southwestern Medical Center

Public Release: 5-Mar-2014
Practical Radiation Oncology
ASTRO white paper provides guidance for optimal quality, safety of HDR brachytherapy
The American Society for Radiation Oncology has issued a new white paper, 'A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy,' that recommends specific guidance to follow in the delivery of high-dose-rate brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO.

Contact: Brittany Ashcroft
American Society for Radiation Oncology

Public Release: 5-Mar-2014
Journal of Biological Chemistry
New molecules doom proteins with kiss of death
Like mobsters following strict orders, newly engineered molecules called 'ubiquibodies' can mark specific proteins inside a cell for destruction. It's a molecular kiss of death developed at Cornell University that is paving the way for new drug therapies and powerful research tools.
National Institutes of Health

Contact: Syl Kacapyr
Cornell University

Public Release: 4-Mar-2014
Molecular Cancer Research
TGen identifies key protein that helps prevent lung cancer tumors from being destroyed
Researchers at the Translational Genomics Research Institute have discovered a protein, Mcl-1, that helps enable one of the most common and deadly types of cancer to survive radiation and drug treatments. In a new laboratory study published in the scientific journal Molecular Cancer Research, TGen investigators found that a protein called Mcl-1 helps enable TWEAK-Fn14, which in turn helps protect NSCLC tumors from being destroyed by radiation and drugs.
National Institutes of Health

Contact: Steve Yozwiak
The Translational Genomics Research Institute

Public Release: 4-Mar-2014
Journal of Clinical Oncology
Investigational drug may increase survival for some patients with advanced melanoma
An experimental drug aimed at restoring the immune system's ability to spot and attack cancer-halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multi-site, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments.

Contact: Vanessa Wasta
Johns Hopkins Medicine

Public Release: 4-Mar-2014
Cell Metabolism
Cholesterol study suggests new diagnostic, treatment approach for prostate cancer
Researchers have discovered a link between prostate cancer aggressiveness and the accumulation of a compound produced when cholesterol is metabolized in cells, findings that could bring new diagnostic and treatment methods. Findings also suggest that a class of drugs previously developed to treat atherosclerosis might be repurposed for treatment of advanced prostate cancer.
National Institutes of Health, National Science Foundation, US Department of Defense

Contact: Emil Venere
Purdue University

Public Release: 4-Mar-2014
Common cancers evade detection by silencing parts of immune system cells
Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body's immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment.
NIH/National Cancer Institute, Stand Up to Cancer, Epigenetic Dream Team

Contact: Stephanie Desmon
Johns Hopkins Medicine

Public Release: 4-Mar-2014
Brain, Behavior and Immunity
Imprint of chemotherapy linked to inflammation in breast cancer survivors
Chemotherapy can leave a long-lasting epigenetic imprint in the DNA of breast cancer patients' blood cells. That imprint is associated with biological signs of inflammation up to six months after the completion of treatment.
NIH/National Cancer Institute

Contact: Quinn Eastman
Emory Health Sciences

Showing releases 1001-1025 out of 1284.

<< < 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>

  Search News Releases